Grace Therapeutics (GRCE) Expected to Announce Earnings on Monday

Grace Therapeutics (NASDAQ:GRCE) is projected to announce its Q4 2026 results before the market opens on Monday, June 22nd. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $0.90 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2026 earning overview page for the latest details on the call scheduled for Tuesday, June 23, 2026 at 9:30 AM ET.

Grace Therapeutics Stock Performance

Grace Therapeutics stock opened at $2.20 on Monday. Grace Therapeutics has a 12-month low of $1.79 and a 12-month high of $5.18. The firm has a 50-day moving average price of $2.88 and a 200-day moving average price of $3.44. The firm has a market capitalization of $34.03 million, a PE ratio of -5.50 and a beta of 0.37.

Institutional Trading of Grace Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. SeaCrest Wealth Management LLC acquired a new stake in Grace Therapeutics during the 3rd quarter valued at approximately $42,000. XTX Topco Ltd acquired a new stake in shares of Grace Therapeutics in the fourth quarter worth $106,000. Renaissance Technologies LLC raised its holdings in shares of Grace Therapeutics by 53.5% during the fourth quarter. Renaissance Technologies LLC now owns 129,781 shares of the company’s stock worth $449,000 after purchasing an additional 45,220 shares during the last quarter. ADAR1 Capital Management LLC raised its holdings in shares of Grace Therapeutics by 98.4% during the third quarter. ADAR1 Capital Management LLC now owns 350,450 shares of the company’s stock worth $1,043,000 after purchasing an additional 173,823 shares during the last quarter. Finally, Cerity Partners LLC acquired a new position in Grace Therapeutics during the fourth quarter valued at $1,463,000. 6.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on GRCE shares. Craig Hallum set a $4.00 price objective on shares of Grace Therapeutics in a research report on Friday, April 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Grace Therapeutics in a research report on Tuesday, April 21st. Wall Street Zen downgraded shares of Grace Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 23rd. Finally, TD Cowen lowered their price target on Grace Therapeutics from $12.00 to $8.00 and set a “buy” rating for the company in a report on Friday, April 24th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Grace Therapeutics has an average rating of “Hold” and a consensus price target of $6.00.

Grace Therapeutics Company Profile

Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.